Literature DB >> 12243243

Use of hylan B gel as a wound dressing after endoscopic sinus surgery.

Saul Frenkiel1, Martin Y Desrosiers, Dan Nachtigal.   

Abstract

Although serious sequelae of endoscopic sinus surgery are infrequent, more commonplace surgical management often involves the control of mucosal bleeding. This study was conducted to assess the efficacy of an elastoviscous hylan gel as a postsurgical wound dressing for promotion of hemostasis. Twenty patients with a diagnosis of chronic sinusitis were evaluated. In randomized fashion, the gel dressing was placed into one operated cavity while the contralateral side served as the control. The results indicated that hylan gel was effective in stilling postsurgical bleeding, particularly in the fulminant polyposis cases who had a larger and more exposed cavity. These early results indicate a potential benefit of a gel dressing for hemostasis when used at the conclusion of the operative procedure. In addition, other parameters were evaluated in this study, including prevention of postoperative adhesions and the effect on mucosal healing. These parameters showed a positive result compared with the control group.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12243243     DOI: 10.2310/7070.2002.21296

Source DB:  PubMed          Journal:  J Otolaryngol        ISSN: 0381-6605


  3 in total

1.  Advances in the surgical management of chronic rhinosinusitis.

Authors:  Erin D Wright; Saul Frenkiel
Journal:  Allergy Asthma Clin Immunol       Date:  2005-03-15       Impact factor: 3.406

Review 2.  [Wound healing after endoscopic sinus surgery and postoperative management].

Authors:  A G Beule; W Hosemann
Journal:  HNO       Date:  2009-08       Impact factor: 1.284

Review 3.  How effective is postoperative packing in FESS patients? A critical analysis of published interventional studies.

Authors:  Petros V Vlastarakos; Emily Iacovou; Melina Fetta; Marios Tapis; Thomas P Nikolopoulos
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-12-26       Impact factor: 2.503

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.